MEI Pharma, Inc.

This stock has a reasonable momentum. MEI Pharma, Inc. is a mediocre stock to choose.

MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candida...

News

MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average of $3.29

Zolmax MEI Pharma, Inc. (NASDAQ:MEIP - Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.29 and traded as low as...\n more…

MEI Pharma (NASDAQ:MEIP) Shares Pass Below 200-Day Moving Average of $3.29

Ticker Report MEI Pharma, Inc. (NASDAQ:MEIP - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.29 and traded as low...\n more…

MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com

Zolmax Equities research analysts at StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP - Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage...\n more…

MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average of $3.40

Ticker Report MEI Pharma, Inc. (NASDAQ:MEIP - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.40 and traded as low as...\n more…

MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com

Ticker Report Stock analysts at StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP - Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a "buy" rating...\n more…

MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com

Ticker Report StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP - Free Report) in a research note released on Monday morning. The brokerage issued a buy rating on the stock. Several other...\n more…